106 related articles for article (PubMed ID: 12522946)
1. State of the art treatment of the most difficult low density lipoprotein (LDL) cholesterol problems: LDL apheresis.
Whayne TF; Zielke JC; Dickson LG; Winters JL
J Ky Med Assoc; 2002 Dec; 100(12):535-8. PubMed ID: 12522946
[TBL] [Abstract][Full Text] [Related]
2. Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia.
Coker M; Ucar SK; Simsek DG; Darcan S; Bak M; Can S
Ther Apher Dial; 2009 Apr; 13(2):121-8. PubMed ID: 19379151
[TBL] [Abstract][Full Text] [Related]
3. [Selection criteria for treatment of severe hyperlipoproteinemias with LDL apheresis].
Bláha V; Zadák Z; Bláha M; Havel E; Solichová D; Brátová M; Malý J; Kmonícek L
Cas Lek Cesk; 1998 Jul; 137(14):424-9. PubMed ID: 9748737
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol.
Opole IO; Belmont JM; Kumar A; Moriarty PM
Am J Cardiol; 2007 Nov; 100(9):1416-8. PubMed ID: 17950800
[TBL] [Abstract][Full Text] [Related]
5. Is lipoprotein (a)-apheresis useful?
Bambauer R
Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia.
Sachais BS; Katz J; Ross J; Rader DJ
J Clin Apher; 2005 Dec; 20(4):252-5. PubMed ID: 15880364
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different LDL apheresis methods.
Julius U; Frind A; Tselmin S; Kopprasch S; Poberschin I; Siegert G
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):629-39. PubMed ID: 18510481
[TBL] [Abstract][Full Text] [Related]
8. [Effects of LDL-apheresis--more than reduction of cholesterol?].
Schettler V; Wieland E
Dtsch Med Wochenschr; 2007 Mar; 132(11):575-8. PubMed ID: 17342636
[TBL] [Abstract][Full Text] [Related]
9. Direct adsorption of lipoproteins from whole blood by direct adsorption of lipoprotein apheresis: first experience in two hypercholesterolemic children.
Bayrakci US; Besbas N; Ozcebe O; Coskun T; Akgul E; Kutluk T; Bakkaloglu A
Ther Apher Dial; 2005 Dec; 9(6):469-72. PubMed ID: 16354278
[TBL] [Abstract][Full Text] [Related]
10. [Apheresis in severe hypercholesterolaemia].
Graesdal A; Hovland A; Bjørbaek E
Tidsskr Nor Laegeforen; 2004 Apr; 124(8):1085-7. PubMed ID: 15114383
[TBL] [Abstract][Full Text] [Related]
11. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
12. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years.
Palcoux JB; Atassi-Dumont M; Lefevre P; Hequet O; Schlienger JL; Brignon P; Roussel B
Ther Apher Dial; 2008 Jun; 12(3):195-201. PubMed ID: 18503695
[TBL] [Abstract][Full Text] [Related]
14. Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL-apheresis.
Stefanutti C; Lucani G; Vivenzio A; Di Giacomo S; Lucani E; Mazzarella B
Clin Ter; 1998; 149(3):231-3. PubMed ID: 9842108
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
Liska B; Khattab AA; Herrmann L; Abdel-Wahab M; Westphal R; Tölg R; Geist V; Richardt G
Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
[TBL] [Abstract][Full Text] [Related]
16. Lipidfiltration--safe and effective methodology to perform lipid-apheresis.
Klingel R; Mausfeld P; Fassbender C; Goehlen B
Transfus Apher Sci; 2004 Jun; 30(3):245-54. PubMed ID: 15172630
[TBL] [Abstract][Full Text] [Related]
17. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
[TBL] [Abstract][Full Text] [Related]
19. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
20. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.
Temelkova-Kurktschiev T; Hanefeld M
Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):75-9. PubMed ID: 15031770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
